Skin cancer is the most frequently diagnosed cancer in the United States. The Skin Cancer Foundation reports that more than 9,500 Americans are diagnosed with skin cancer every day, and approximately 1 in 5 Americans will develop skin cancer by age 70. The mortality calculus is unambiguous: melanoma detected at Stage I has a 5-year survival rate of 98%; at Stage IV, that drops to 28%. Early detection saves lives in a way that is statistically direct and measurable.
Yet the infrastructure for systematic skin cancer screening is inconsistent. Dermatology practices run free community screening events, participate in melanoma awareness campaigns, and maintain internal recall systems for high-risk patients — but the administrative demands of coordinating these programs, managing the biopsy follow-up that flows from them, and sustaining patient reminder systems often exceed what in-house staff can handle without a dedicated system.
Virtual assistants are filling that operational gap in skin cancer screening centers and dermatology practices with active screening programs.
Community Screening Event Coordination
Free skin cancer screening events — tied to Melanoma Monday in May, or run independently throughout the year — generate significant community goodwill, new patient acquisition, and early detection outcomes. But they require substantial advance coordination:
- Provider scheduling — coordinating which physicians and PAs are volunteering or assigned to each screening session and managing their availability
- Patient registration — managing online or phone registration for screening slots, sending confirmation and pre-screening instructions
- Community partner coordination — working with employers, community organizations, or health systems that are co-hosting events
- Equipment and supply logistics — confirming dermatoscopes, biopsy kits, patient registration materials, and consent forms are ready before each event
- Post-event follow-up — contacting every screening participant whose exam identified a suspicious lesion requiring biopsy or prompt follow-up appointment
A VA can own the full coordination lifecycle for screening events — from initial planning to post-event patient follow-up — freeing clinical staff to focus on the examinations themselves.
Biopsy Follow-Up: The Critical Safety Function
Every skin cancer screening event generates a follow-up pipeline: patients with suspicious lesions who need a biopsy appointment, biopsy results that need to be communicated and acted upon, and patients diagnosed with skin cancer who need to be entered into a treatment and surveillance program.
Managing this pipeline is a safety-critical function. The Journal of the American Academy of Dermatology has documented that 15–20% of dermatology biopsy results are not communicated to patients within clinically appropriate timeframes — a gap that delays diagnosis, increases patient anxiety, and creates medical-legal exposure for practices.
A skin cancer screening VA manages the biopsy follow-up pipeline:
- Pending biopsy tracking — maintaining a real-time log of all biopsies submitted, with expected result turnaround dates from each pathology lab
- Result receipt confirmation — confirming pathology reports are received into the EHR and assigned to the ordering provider for review
- Patient notification coordination — once the physician has reviewed results, executing the notification protocol: benign results communicated via portal message, concerning results flagged for physician phone call
- Malignant result follow-up — for patients diagnosed with melanoma, basal cell, or squamous cell carcinoma, coordinating the next appointment within the required clinical timeframe (typically within 1–2 weeks for melanoma)
- Biopsy result documentation — ensuring all results are documented in the chart in a way that supports accurate coding and quality metric reporting
Patient Reminder Systems for High-Risk Surveillance
Patients with a prior skin cancer diagnosis, significant family history, or high-risk phenotype (multiple atypical nevi, fair skin, extensive sun exposure history) require structured annual or biannual full-body skin examinations. Without a recall system, these high-risk patients fall through the gap — returning to the practice only when they notice a new lesion, often at a more advanced stage.
A VA builds and operates the patient reminder system:
- Pulling a report from the EHR of patients due for surveillance exams in the coming 30–60 days based on their documented recall interval
- Executing an outreach sequence: portal message, SMS reminder, and outbound phone call for non-responders
- Scheduling surveillance appointments and confirming them 48 hours in advance
- Tracking patients who decline scheduling and flagging them for clinical team review at 90 days
The Skin Cancer Foundation's data shows that patients enrolled in formal surveillance programs are 3x more likely to have skin cancers detected at Stage I compared to those who return only when symptomatic. The VA-operated recall system is the operational backbone of that surveillance advantage.
High-Risk Patient Identification and Outreach
Dermatology practices with large patient databases often have unidentified high-risk patients — those who had a melanoma removed years ago and were never entered into a formal recall system, or those who received a high-risk biopsy result that was communicated but whose surveillance scheduling lapsed. A VA can conduct a systematic audit of the patient database to identify these gaps and initiate outreach to bring them back into active surveillance.
This one-time initiative often uncovers dozens or hundreds of patients who have fallen out of surveillance — a patient safety and revenue recovery opportunity simultaneously.
For skin cancer screening centers building systematic early detection programs, Stealth Agents provides trained medical administrative VAs who can be deployed into screening and surveillance workflows quickly.
Sources
- Skin Cancer Foundation — Skin Cancer Facts and Statistics, 2025
- Journal of the American Academy of Dermatology — Biopsy Result Communication Timeliness Study, 2023
- National Cancer Institute — SEER Cancer Survival Data: Melanoma by Stage, 2024